SCHEMBL3354024

SCHEMBL3354024

NC(=O)c1ccc2c(c1)CCS2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 2/20 0.43
HDAC1 Q13547 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
SIRT2 Q8IXJ6 2/20 0.40
TSHR P16473 1/20 0.40
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
HSD17B3 P37058 1/20 0.38
LCK P06239 1/20 0.38
RYR2 Q92736 1/20 0.38
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HSD17B10 Q99714 1/20 0.36
PARP1 P09874 5/20 0.36
MEN1 O00255 1/20 0.36
CYP1A2 P05177 1/20 0.36
HPGD P15428 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3348087 0.86 KDM1A (0.43) KDM1AHDAC1HDAC8HDAC6SIRT2
SCHEMBL7759522 0.84 ALDH1A1 (0.52) KDM1AHDAC1HDAC8HDAC6TSHR
SCHEMBL1865789 0.82 MAPT (0.50) HDAC1HDAC8HDAC6POLBGAA
SCHEMBL11232725 0.82 CPT1B (0.39) HDAC1HDAC8HDAC6POLBGAA
SCHEMBL3142775 0.78 ALDH1A1 (0.57) POLBGAAMAPTKDM4EALDH1A1
SCHEMBL10687927 0.78 ATM (0.44) HDAC1HDAC8HDAC6TSHRPOLB
SCHEMBL8110167 0.77 RYR2 (0.40) HDAC1HDAC8HDAC6POLBGAA
SCHEMBL25569790 0.76 HPGD (0.47) GAAMAPTHSD17B3KDM4EALDH1A1
SCHEMBL7098217 0.76 ALDH1A1 (0.40) HDAC1HDAC8HDAC6POLBGAA
SCHEMBL6973452 0.74 MAPT (0.60) POLBGAAMAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7727997-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2010-06-01 US disclosed
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US disclosed
US-7176242-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2007-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease BACE1, BACE2, APP KDM1A 4199/4885HDAC1 426/4885HDAC8 2081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.